Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Other Non Operating Income (2018 - 2025)

10x Genomics' Other Non Operating Income history spans 8 years, with the latest figure at -$2.5 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 16.56% year-over-year to -$2.5 million; the TTM value through Dec 2025 reached $1.0 million, up 149.83%, while the annual FY2025 figure was $1.0 million, 149.83% up from the prior year.
  • Other Non Operating Income for Q4 2025 was -$2.5 million at 10x Genomics, down from -$1.2 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $4.0 million in Q4 2022 and bottomed at -$3.0 million in Q4 2024.
  • The 5-year median for Other Non Operating Income is -$729000.0 (2021), against an average of -$149684.2.
  • The largest annual shift saw Other Non Operating Income plummeted 659.38% in 2021 before it soared 79800.0% in 2022.
  • A 5-year view of Other Non Operating Income shows it stood at $5000.0 in 2021, then skyrocketed by 79800.0% to $4.0 million in 2022, then fell by 0.33% to $4.0 million in 2023, then tumbled by 176.57% to -$3.0 million in 2024, then rose by 16.56% to -$2.5 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Other Non Operating Income are -$2.5 million (Q4 2025), -$1.2 million (Q3 2025), and $2.6 million (Q2 2025).